Dendrite's Salesplus Europe Signs Tecnifar Portugal and Bioderma France; Tecnifar Marks First Dendrite Client in Portugal.

Business/Health Editors

MORRISTOWN, N.J.--(BUSINESS WIRE)--April 13, 2000

Dendrite International, Inc. (NASDAQ/NMS:DRTE) today announced that its SalesPlus Europe division has signed licensing agreements with Tecnifar, a Portuguese pharmaceutical company, and Bioderma, a dermatological division of Holland-based Ogekos. These agreements include SalesPlus software and support services for the Bioderma sales forces in France and for Tecnifar in Portugal.

SalesPlus Europe is a sales force effectiveness (SFE) system exclusively designed for the European pharmaceutical industry. SalesPlus has also been designed to encourage rapid acceptance by the field force, thus helping medical representatives remain ahead of the competition. SalesPlus has been developed in the knowledge that pharmaceutical companies need to manage more complex information with the right analytical reporting tools and this at all organization levels.

Jean-Marie Pereira de Castro, Sales & Marketing Director of Tecnifar, said, "We selected SalesPlus because we feel that it is a management tool which supplies the most accurate information related to the critical areas of growth as defined by Tecnifar's mission, philosophy and culture."

"In step with the globalization of Dendrite's client base, we are extremely proud to announce SalesPlus Europe's agreement with Tecnifar, which not only builds upon Dendrite's solid presence throughout Europe, but which also marks our advancement into the Portuguese market," said John Bailye, Chairman and CEO of Dendrite International. "Additionally, our agreement with Bioderma offers Dendrite another opportunity to assist a European sales force in optimizing resources and maximizing effectiveness."

Bioderma reviewed SFE systems from IMS Health and others before choosing Dendrite's Sales Plus solution for its sales forces in France. Dendrite was signed for three years as a result of past success with similar companies and was the only vendor to provide the appropriate module Bioderma was requesting.

ABOUT TECNIFAR PORTUGAL

Tecnifar is a Portuguese Pharmaceutical Laboratory with 100% national capital that works exclusively in the national market. Main products are in the following areas: Neuro-psychiatry, Cardiology, Orthopedics, Gynecology, and General Practice. Among our range of products, we highlight those licensed by: Merck Sharp & Dohme (lovastatin, enalapril maleate and sodium alendronate), Roche (cefetamet piroxil) and Uriach (triflusal).

ABOUT DENDRITE

As a leading global provider of highly specialized, integrated product and service offerings for the Pharmaceutical and Consumer Package Goods (CPG) industries, Dendrite supports corporate strategies for a sustained competitive advantage. Thousands of sales representatives and their managers from over 150 companies and 57 countries rely on Dendrite for a uniquely tailored combination of tools, information and skills to help them prepare for tomorrow's challenges and improve their sales success. Focusing strongly on outcomes, Dendrite combines its modular software products with specifically tailored coaching and support services. With a global infrastructure as its foundation, Dendrite's commitment to unparalleled service has been the hallmark of the business and the basis of strong customer loyalty since the Company's inception in 1986.

Headquartered in Morristown, New Jersey, Dendrite employs over 1300 people around the world. For more information, visit the Company's Web site at http://www.drte.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

This press release contains statements that are forward-looking statements and discuss expectations about future events or outcomes with respect to Dendrite and its business, including statements regarding expected results for future periods. We believe these statements are within the scope of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and we intend that these statements be covered by the safe harbors created by such acts. The forward-looking statements are based on our current expectations, assumptions, estimates and projections about our company and the pharmaceutical and consumer packaged goods industries and involve risks and uncertainties. Accordingly, Dendrite's actual results may differ materially from the results discussed in or implied by such forward-looking statements. The risk factors that could cause actual results to differ from the results expressed or implied by these forward-looking statements include the following: (i) our business is heavily dependent on the pharmaceutical industry; (ii) our quarterly results of operations may fluctuate significantly and may not meet market expectations; (iii) our lengthy sales and implementation cycles make it difficult to predict our quarterly revenues; (iv) our fixed costs may lead to fluctuations in our quarterly operating results if revenues fall below expectations; (v) our business is affected by variations in our customers' budget cycles; (vi) our revenues would decline and our business would be adversely affected by the loss of one of our major customers; (vii) we may be unable to successfully introduce new products or respond to technological change; (viii) we are exposed to risks associated with the Year 2000 (for example, (a) demand for our software products and services may decline before and after the Year 2000, (b) our Year 2000 remediation efforts may be unsuccessful and (c) we may incur material expenses in connection with any claim relating to Year 2000 compliance of our own products or the products of third parties); (ix) increased competition may result in price reductions and decreased demand for our products and services; (x) some of our customers rely on our competitors for market data; (xi) our international operations have risks that our domestic operations do not; (xii) our success depends on retaining our key senior management team and on attracting and retaining qualified personnel; (xiii) our inability to manage our growth could adversely affect our business; (xiv) our business depends on proprietary technology that we may not be to protect completely; and (xv) the consumer packaged goods industry may have different characteristics from those we are used to in the pharmaceutical industry. In light of the significant uncertainties inherent in these forward-looking statements, you should not consider their inclusion as a representation by us or anyone else that we will achieve our objectives and plans. Moreover, we assume no obligation to update these forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements. For further discussion of these and other factors that could adversely affect Dendrite's financial condition and results of operations consult Dendrite's annual report on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission.